Correlates of therapeutic efficacy in experimental methicillin-resistant Staphylococcus aureus endocarditis.
Seventy animals with experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA) were randomized to receive: no therapy; pefloxacin 40 or 80 mg/kg/day i.v.; or vancomycin 30 mg/kg/day i.v. Vancomycin caused a more rapid decrease in intravegetation MRSA counts than pefloxacin at 40 or 80 mg/kg/day (p less than 0.001, p less than 0.05, respectively, therapy day 3). The major correlate of therapeutic efficacy in this study was the significantly higher mean intravegetation levels achieved by vancomycin (16.8 +/- 6.1 micrograms/g) versus those attained by pefloxacin therapy at either 40 (1.6 +/- 0.13 micrograms/g) or 80 mg/kg/day (2.8 +/- 0.53 micrograms/g, p less than 0.005, p less than 0.025, respectively).
Bayer
A S
AS
Department of Medicine, Harbor-UCLA Medical Center, Torrance, Calif.
Greenberg
D P
DP
Yih
J
J
D000818:Animals; D000890:Anti-Infective Agents / Q000097:blood / Q000627:therapeutic use*; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D008712:Methicillin; D008826:Microbial Sensitivity Tests; D009643:Norfloxacin / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D015366:Pefloxacin; D010403:Penicillin Resistance; D011817:Rabbits; D011897:Random Allocation; D013203:Staphylococcal Infections / Q000188:drug therapy*; D014640:Vancomycin / Q000097:blood / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D015366:Pefloxacin; D014640:Vancomycin; D009643:Norfloxacin; D008712:Methicillin